133599Establishment of Novel Assay Systems to Develop Innovative Disease-Modifying Medicines for AsthmaClosedFeasibility StudiesInnovate UK"Peptinnovate is a clinical stage biotechnology company based at the Stevenage Bioscience Catalyst. The company's core research is based on molecules derived from Mycobacterium tuberculosis proteins, as innovative immunomodulatory agents for the treatment of chronic inflammatory diseases. The lead molecule PIN201104 is a safe, low molecular weight peptide identified by phenotypic drug discovery in collaboration with a number of leading UK academic groups. PIN201104 has progressed into a Phase I clinical study as a first in class, broad spectrum, disease modifying agent for the treatment of asthma and other chronic inflammatory conditions. The receptor target for PIN201104 has recently been identified and is novel in the area of inflammation. As such, this target represents an exciting and innovative area of research for future asthma medicines. This funding opportunity will allow for the establishment of new assays to characterise this potentially novel target for asthma and thus inform on the down stream signalling pathway and also deliver assays for follow-on compound profiling."